secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0000950170-23-039051
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta Q3 loss $1.86/diluted share; revenue $18.9M; positive Phase 1 RSV data
-----------------------------------------------------------------------------

- Net loss $39.1M ($1.86/diluted) vs. $31.7M ($1.53) in prior-year Q3; revenue $18.9M down from $19.5M.
- Cash and marketable securities $392.5M at June 30; sold 54.5% of future royalty to OMERS for $200M.
- Positive Phase 1 data for RSV L-protein inhibitor EDP-323; Phase 2 human challenge study expected early Q4 2023.
- Updated FY2023 guidance: R&D $165M-$175M; G&A $50M-$55M; royalty portion to OMERS from Q4 onward.
- Phase 2 COVID EDP-235 showed 1.0 log viral load drop in nucleocapsid-negative patients treated within 3 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017023039051/0000950170-23-039051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017023039051/enta-20230807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer